Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 165
Filtrar
1.
Front Endocrinol (Lausanne) ; 13: 1019667, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36299462

RESUMEN

Background: The inflammatory response plays a critical role in postoperative nosocomial infections, which are the most common postoperative complications causing adverse events and poor postoperative outcomes. This study aimed to explore the ability of early inflammation-related factor levels to predict the occurrence of nosocomial infections after abdominal surgery. Methods: The study included 146 patients with open abdominal surgery (a nosocomial infection group (NI group, n=42) and a no-nosocomial infection group (NNI group, n=104)). After 1:1 matching, the patients were divided into a matching nosocomial infection group (M-NI group, n=25) and a matching no-nosocomial infection group (M-NNI group, n=25). Serum levels of interleukin (IL)-6, IL-8, IL-10, IL-12, IL-18, macrophage migration inhibitory factor (MIF), and monocyte chemotactic protein (MCP-1) were tested at three time points (pre-operation, 0-hour post-operation (POD1) and 24-hour post-operation (POD2)). The area under the receiver operating characteristic curve (AUC-ROC) was used to test the predictive abilities. Results: There were significant differences in the levels of IL-6, IL-12, and IL-18 between the M-NI and M-NNI groups (p < 0.05), but not in the levels of other inflammatory factors. MIF, IL-8, and MCP-1 levels were higher in the M-NI group than in the M-NNI group at POD2 (p < 0.05). In the ROC analysis, the AUC for prediction of nosocomial infection using a combination of IL-6 and IL-18 at POD1 was 0.9616, while the AUCs for IL-6 alone and IL-12 alone were 0.8584 and 0.8256, respectively. Conclusions: The combination of the levels of inflammatory factors, IL-6 and IL-18, at the 0-hour postoperative time point, significantly improved the predictive ability to the development of postoperative infection during perioperative period. Our study suggests the importance of monitoring postoperative inflammatory markers.


Asunto(s)
Infección Hospitalaria , Interleucina-18 , Interleucina-6 , Proteínas Quimioatrayentes de Monocitos , Humanos , Interleucina-10 , Interleucina-12 , Interleucina-18/sangre , Interleucina-18/inmunología , Interleucina-6/sangre , Interleucina-6/inmunología , Interleucina-8 , Factores Inhibidores de la Migración de Macrófagos , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/inmunología , Biomarcadores/sangre , Abdomen/cirugía , Infección Hospitalaria/sangre , Infección Hospitalaria/inmunología
2.
Epidemiol Infect ; 150: e40, 2022 02 21.
Artículo en Inglés | MEDLINE | ID: mdl-35184772

RESUMEN

Nosocomial transmission of COVID-19 among immunocompromised hosts can have a serious impact on COVID-19 severity, underlying disease progression and SARS-CoV-2 transmission to other patients and healthcare workers within hospitals. We experienced a nosocomial outbreak of COVID-19 in the setting of a daycare unit for paediatric and young adult cancer patients. Between 9 and 18 November 2020, 473 individuals (181 patients, 247 caregivers/siblings and 45 staff members) were exposed to the index case, who was a nursing staff. Among them, three patients and four caregivers were infected. Two 5-year-old cancer patients with COVID-19 were not severely ill, but a 25-year-old cancer patient showed prolonged shedding of SARS-CoV-2 RNA for at least 12 weeks, which probably infected his mother at home approximately 7-8 weeks after the initial diagnosis. Except for this case, no secondary transmission was observed from the confirmed cases in either the hospital or the community. To conclude, in the day care setting of immunocompromised children and young adults, the rate of in-hospital transmission of SARS-CoV-2 was 1.6% when applying the stringent policy of infection prevention and control, including universal mask application and rapid and extensive contact investigation. Severely immunocompromised children/young adults with COVID-19 would have to be carefully managed after the mandatory isolation period while keeping the possibility of prolonged shedding of live virus in mind.


Asunto(s)
COVID-19/epidemiología , Instituciones Oncológicas , Infección Hospitalaria/epidemiología , Centros de Día , Transmisión de Enfermedad Infecciosa de Profesional a Paciente , Neoplasias/terapia , Adolescente , Adulto , Anciano , COVID-19/inmunología , COVID-19/transmisión , Cuidadores , Niño , Preescolar , Infección Hospitalaria/inmunología , Infección Hospitalaria/transmisión , Brotes de Enfermedades , Femenino , Humanos , Huésped Inmunocomprometido , Lactante , Masculino , Persona de Mediana Edad , Neoplasias/inmunología , República de Corea/epidemiología , SARS-CoV-2 , Adulto Joven
3.
J Trauma Acute Care Surg ; 91(1): 47-53, 2021 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-33660689

RESUMEN

BACKGROUND: Flow cytometry (FCM) is a rapid diagnostic tool for monitoring immune cell function. We sought to determine if assessment of cell phenotypes using standardized FCM could be used to identify nosocomial infection after trauma. METHODS: Prospective study of trauma patients at a Level I center from 2014 to 2018. Clinical and FCM data were collected within 24 hours of admission. Random forest (RF) models were developed to estimate the risk of severe sepsis (SS), organ space infection (OSI), and ventilator-associated pneumonia (VAP). Variables were selected using backward elimination and models were validated with leave-one-out. RESULTS: One hundred and thirty-eight patients were included (median age, 30 years [23-44 years]; median Injury Severity Score, 20 (14-29); 76% (105/138) Black; 60% (83/138) gunshots). The incidence of SS was 8.7% (12/138), OSI 16.7% (23/138), and VAP 18% (25/138). The final RF SS model resulted in five variables (RBCs transfused in first 24 hours; absolute counts of CD56- CD16+ lymphocytes, CD4+ T cells, and CD56 bright natural killer [NK] cells; percentage of CD16+ CD56+ NK cells) that identified SS with an AUC of 0.89, sensitivity of 0.98, and specificity of 0.78. The final RF OSI model resulted in four variables (RBC in first 24 hours, shock index, absolute CD16+ CD56+ NK cell counts, percentage of CD56 bright NK cells) that identified OSI with an AUC of 0.76, sensitivity of 0.68, and specificity of 0.82. The RF VAP model resulted in six variables (Sequential [Sepsis-related] Organ Failure Assessment score: Injury Severity Score; CD4- CD8- T cell counts; percentages of CD16- CD56- NK cells, CD16- CD56+ NK cells, and CD19+ B lymphocytes) that identified VAP with AUC of 0.86, sensitivity of 0.86, and specificity of 0.83. CONCLUSIONS: Combined clinical and FCM data can assist with early identification of posttraumatic infections. The presence of NK cells supports the innate immune response that occurs during acute inflammation. Further research is needed to determine the functional role of these innate cell phenotypes and their value in predictive models immediately after injury. LEVEL OF EVIDENCE: Prognostic, level III.


Asunto(s)
Infección Hospitalaria/diagnóstico , Células Asesinas Naturales/inmunología , Modelos Biológicos , Heridas y Lesiones/complicaciones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Infección Hospitalaria/sangre , Infección Hospitalaria/inmunología , Estudios de Factibilidad , Femenino , Citometría de Flujo , Humanos , Inmunidad Innata , Puntaje de Gravedad del Traumatismo , Tiempo de Internación/estadística & datos numéricos , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sensibilidad y Especificidad , Heridas y Lesiones/sangre , Heridas y Lesiones/diagnóstico , Heridas y Lesiones/inmunología , Adulto Joven
4.
Sci Rep ; 11(1): 7154, 2021 03 30.
Artículo en Inglés | MEDLINE | ID: mdl-33785781

RESUMEN

Pseudomonas aeruginosa (PA) is a leading cause of nosocomial infections and death in cystic fibrosis patients. The study was conducted to evaluate the physicochemical structure, biological activity and serum stability of a recombinant anti-PcrV single chain variable antibody fragment genetically attached to the mCH3cc domain. The stereochemical properties of scFv-mCH3 (YFL001) and scFv (YFL002) proteins as well as molecular interactions towards Pseudomonas aeruginosa PcrV were evaluated computationally. The subcloned fragments encoding YFL001 and YFL002 in pET28a were expressed within the E. coli BL21-DE3 strain. After Ni-NTA affinity chromatography, the biological activity of the proteins in inhibition of PA induced hemolysis as well as cellular cytotoxicity was assessed. In silico analysis revealed the satisfactory stereochemical quality of the models as well as common residues in their interface with PcrV. The structural differences of proteins through circular dichroism spectroscopy were confirmed by NMR analysis. Both proteins indicated inhibition of ExoU positive PA strains in hemolysis of red blood cells compared to ExoU negative strains as well as cytotoxicity effect on lung epithelial cells. The ELISA test showed the longer serum stability of the YFL001 molecule than YFL002. The results were encouraging to further evaluation of these two scFv molecules in animal models.


Asunto(s)
Antibacterianos/farmacología , Toxinas Bacterianas/antagonistas & inhibidores , Infección Hospitalaria/tratamiento farmacológico , Proteínas Citotóxicas Formadoras de Poros/antagonistas & inhibidores , Infecciones por Pseudomonas/tratamiento farmacológico , Anticuerpos de Cadena Única/farmacología , Antibacterianos/aislamiento & purificación , Antibacterianos/uso terapéutico , Antígenos Bacterianos/metabolismo , Toxinas Bacterianas/metabolismo , Línea Celular Tumoral , Clonación Molecular , Simulación por Computador , Infección Hospitalaria/inmunología , Infección Hospitalaria/microbiología , Semivida , Humanos , Simulación del Acoplamiento Molecular , Proteínas Citotóxicas Formadoras de Poros/metabolismo , Infecciones por Pseudomonas/inmunología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/inmunología , Proteínas Recombinantes/genética , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Anticuerpos de Cadena Única/genética , Anticuerpos de Cadena Única/aislamiento & purificación , Anticuerpos de Cadena Única/uso terapéutico
5.
J Neuroinflammation ; 18(1): 72, 2021 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-33731173

RESUMEN

BACKGROUND: Traumatic brain injury (TBI) is a major cause of disability in young children, yet the factors contributing to poor outcomes in this population are not well understood. TBI patients are highly susceptible to nosocomial infections, which are mostly acquired within the first week of hospitalization, and such infections may modify TBI pathobiology and recovery. In this study, we hypothesized that a peripheral immune challenge such as lipopolysaccharide (LPS)-mimicking a hospital-acquired infection-would worsen outcomes after experimental pediatric TBI, by perpetuating the inflammatory immune response. METHODS: Three-week-old male mice received either a moderate controlled cortical impact or sham surgery, followed by a single LPS dose (1 mg/kg i.p.) or vehicle (0.9% saline) at 4 days post-surgery, then analysis at 5 or 8 days post-injury (i.e., 1 or 4 days post-LPS). RESULTS: LPS-treated mice exhibited a time-dependent reduction in general activity and social investigation, and increased anxiety, alongside substantial body weight loss, indicating transient sickness behaviors. Spleen-to-body weight ratios were also increased in LPS-treated mice, indicative of persistent activation of adaptive immunity at 4 days post-LPS. TBI + LPS mice showed an impaired trajectory of weight gain post-LPS, reflecting a synergistic effect of TBI and the LPS-induced immune challenge. Flow cytometry analysis demonstrated innate immune cell activation in blood, brain, and spleen post-LPS; however, this was not potentiated by TBI. Cytokine protein levels in serum, and gene expression levels in the brain, were altered in response to LPS but not TBI across the time course. Immunofluorescence analysis of brain sections revealed increased glia reactivity due to injury, but no additive effect of LPS was observed. CONCLUSIONS: Together, we found that a transient, infection-like systemic challenge had widespread effects on the brain and immune system, but these were not synergistic with prior TBI in pediatric mice. These findings provide novel insight into the potential influence of a secondary immune challenge to the injured pediatric brain, with future studies needed to elucidate the chronic effects of this two-hit insult.


Asunto(s)
Lesiones Traumáticas del Encéfalo/inmunología , Lesiones Traumáticas del Encéfalo/patología , Infección Hospitalaria/inmunología , Encefalitis/inmunología , Encefalitis/patología , Inmunidad Adaptativa/inmunología , Animales , Ansiedad/etiología , Ansiedad/psicología , Conducta Animal , Lesiones Traumáticas del Encéfalo/psicología , Corteza Cerebral/patología , Modelos Animales de Enfermedad , Encefalitis/psicología , Lipopolisacáridos/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Actividad Motora , Conducta Social , Pérdida de Peso
6.
Ann Thorac Surg ; 111(5): 1636-1642, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-32652073

RESUMEN

BACKGROUND: Monocytic human leukocyte antigen DR (mHLA-DR) expression levels have been reported to be a marker of immunosuppression and a predictor of sepsis and mortality. There are, however, scant data regarding mHLA-DR monitoring in young infants after cardiopulmonary bypass. Our objectives were to investigate the kinetics of mHLA-DR expression and to determine whether mHLA-DR levels are associated with healthcare-associated infection (HAI) after cardiopulmonary bypass in young infants. METHODS: mHLA-DR levels were analyzed by flow cytometry using a standardized method in 49 infants (<3 months old) with congenital heart disease before and after cardiopulmonary bypass. Results are expressed as the number of anti-HLA-DR antibodies per cell (AB/c). RESULTS: Postoperative mHLA-DR expression was reduced in all infants. Eleven patients (22%) developed HAI, and 4 patients (8%) died during the 30-day follow-up. mHLA-DR expression was significantly lower on postoperative day 4 in the HAI group compared with those who without HAI (3768 AB/c [range, 1938-6144] vs 13,230 AB/c [range, 6152-19,130], P = .014). Although mHLA-DR expression was associated with postoperative severity, mHLA-DR ≤4500 AB/c in the first 72 hours among patients with higher postoperative severity (extracorporeal membrane oxygenation and/or corticoids and/or delayed closure of sternum) was associated with occurrence of HAI in the univariate analysis (odds ratio, 6.3; 95% confidence interval, 1.0-38.7; P = .037). CONCLUSIONS: Cardiopulmonary bypass induces a profound decrease in mHLA-DR expression in young infants. Among patients with higher postoperative severity, low level of mHLA-DR in the early postoperative period is associated with the development of HAI.


Asunto(s)
Puente Cardiopulmonar , Infección Hospitalaria/sangre , Infección Hospitalaria/inmunología , Antígenos HLA-DR/biosíntesis , Antígenos HLA-DR/sangre , Cardiopatías Congénitas/cirugía , Monocitos/inmunología , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/inmunología , Infección Hospitalaria/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Complicaciones Posoperatorias/epidemiología , Estudios Prospectivos
7.
J Trauma Acute Care Surg ; 90(2): 257-267, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-33214489

RESUMEN

BACKGROUND: The genomic/cytokine "storm" after severe trauma is well described. However, the differing composition, magnitude and resolution of this response, and its relationship to clinical outcomes remain unclear. METHODS: This is a secondary analysis of a prospective longitudinal cohort study of severely injured trauma patients in hemorrhagic shock. Peripheral blood sampling was performed at 0.5, 1, 4, 7, 14, and 28 days after injury for measurement of circulating immune biomarkers. K-means clustering using overall mean and trajectory slope of selected immunologic biomarkers were used to identify distinct temporal immunologic endotypes. Endotypes were compared with known clinical trajectories defined as early death (<14 days), chronic critical illness (CCI) (ICU length of stay of ≥14 days with persistent organ dysfunction), and rapid recovery (RAP) (ICU length of stay of <14 days with organ recovery). RESULTS: The cohort included 102 subjects enrolled across 2 level 1 trauma centers. We identified three distinct immunologic endotypes (iA, iB, and iC), each with unique associations to clinical trajectory. Endotype iA (n = 47) exhibited a moderate initial proinflammatory response followed by a return to immunologic homeostasis, with a primary clinical trajectory of RAP (n = 44, 93.6%). Endotype iB (n = 44) exhibited an early hyperinflammatory response with persistent inflammation and immunosuppression, with the highest incidence of CCI (n = 10, 22.7%). Endotype iC (n = 11) exhibited a similar hyperinflammatory response, but with rapid return to immunologic homeostasis and a predominant trajectory of RAP (n = 9, 81.8%). Patients with endotype iB had the highest severity/duration of organ dysfunction and highest incidence of nosocomial infections (50%, p = 0.001), and endotype iB was the predominant endotype of patients who developed CCI (10 of 13 patients, 76.9%; p = 0.002). CONCLUSION: We identified three distinct immunologic endotypes after severe injury differing the magnitude and duration of the early response. The clinical trajectory of CCI is characterized by an endotype (iB) defined by persistent alteration in inflammation/immunosuppression and is associated with poor clinical outcomes. LEVEL OF EVIDENCE: Prognostic, level III.


Asunto(s)
Síndrome de Liberación de Citoquinas/inmunología , Endofenotipos , Choque Hemorrágico/inmunología , Heridas no Penetrantes/inmunología , Biomarcadores/sangre , Estudios de Cohortes , Infección Hospitalaria/inmunología , Infección Hospitalaria/terapia , Síndrome de Liberación de Citoquinas/terapia , Estudios de Seguimiento , Humanos , Terapia de Inmunosupresión , Tiempo de Internación , Estudios Longitudinales , Estudios Prospectivos , Choque Hemorrágico/terapia , Síndrome de Respuesta Inflamatoria Sistémica/inmunología , Síndrome de Respuesta Inflamatoria Sistémica/terapia , Centros Traumatológicos , Resultado del Tratamiento , Heridas no Penetrantes/terapia
8.
Future Microbiol ; 15: 1425-1430, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-33156702

RESUMEN

Aim: Strict endotoxin limits are enforced for implants and catheters inserted into the body. However, no standard limit has been set for single-use sterile surgical gloves. Materials & methods: Four types of gloves sold in Japan were dipped in saline and that endotoxin levels were measured. Cytokine producing activity of gloves in blood was also measured. Results: Three of the four types of gloves showed endotoxin contamination. We also confirmed an increase in cytokine production in these gloves except one glove in which anionic surfactants was found. Conclusion: The extent to which detected endotoxins enter the body during surgery is controversial, but strict endotoxin limits need to be established.


Asunto(s)
Endotoxinas/análisis , Contaminación de Equipos/estadística & datos numéricos , Guantes Quirúrgicos/efectos adversos , Infección Hospitalaria/sangre , Infección Hospitalaria/inmunología , Citocinas/inmunología , Humanos , Procedimientos Quirúrgicos Operativos
9.
Transpl Infect Dis ; 22(6): e13364, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32521074

RESUMEN

Solid organ transplant recipients are considered at high risk for COVID-19 infection due to chronic immune suppression; little data currently exists on the manifestations and outcomes of COVID-19 infection in lung transplant recipients. Here we report 8 cases of COVID-19 identified in patients with a history of lung transplant. We describe the clinical course of disease as well as preexisting characteristics of these patients.


Asunto(s)
COVID-19/fisiopatología , Infección Hospitalaria/fisiopatología , Inmunosupresores/uso terapéutico , Trasplante de Pulmón , Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/uso terapéutico , Adulto , Anciano , Alanina/análogos & derivados , Alanina/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antivirales/uso terapéutico , COVID-19/diagnóstico por imagen , COVID-19/inmunología , COVID-19/terapia , Tos/fisiopatología , Infección Hospitalaria/diagnóstico por imagen , Infección Hospitalaria/inmunología , Infección Hospitalaria/terapia , Fibrosis Quística/cirugía , Disnea/fisiopatología , Femenino , Fiebre/fisiopatología , Enfermedades Gastrointestinales/fisiopatología , Glucocorticoides/uso terapéutico , Rechazo de Injerto/prevención & control , Humanos , Fibrosis Pulmonar Idiopática/cirugía , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Pulmón/diagnóstico por imagen , Masculino , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Pancreatitis Aguda Necrotizante , Enfermedad Pulmonar Obstructiva Crónica/cirugía , Quimioterapia por Pulso , SARS-CoV-2 , Sepsis , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X
10.
mBio ; 11(3)2020 05 26.
Artículo en Inglés | MEDLINE | ID: mdl-32457246

RESUMEN

There is a pressing need for biomarker-based models to predict mortality from and recurrence of Clostridioides difficile infection (CDI). Risk stratification would enable targeted interventions such as fecal microbiota transplant, antitoxin antibodies, and colectomy for those at highest risk. Because severity of CDI is associated with the immune response, we immune profiled patients at the time of diagnosis. The levels of 17 cytokines in plasma were measured in 341 CDI inpatients. The primary outcome of interest was 90-day mortality. Increased tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), C-C motif chemokine ligand 5 (CCL-5), suppression of tumorigenicity 2 receptor (sST-2), IL-8, and IL-15 predicted mortality by univariate analysis. After adjusting for demographics and clinical characteristics, the mortality risk (as indicated by the hazard ratio [HR]) was higher for patients in the top 25th percentile for TNF-α (HR = 8.35, P = 0.005) and IL-8 (HR = 4.45, P = 0.01) and lower for CCL-5 (HR = 0.18, P ≤ 0.008). A logistic regression risk prediction model was developed and had an area under the receiver operating characteristic curve (AUC) of 0.91 for 90-day mortality and 0.77 for 90-day recurrence. While limited by being single site and retrospective, our work resulted in a model with a substantially greater predictive ability than white blood cell count. In conclusion, immune profiling demonstrated differences between patients in their response to CDI, offering the promise for precision medicine individualized treatment.IMPORTANCEClostridioides difficile infection is the most common health care-associated infection in the United States with more than 20% patients experiencing symptomatic recurrence. The complex nature of host-bacterium interactions makes it difficult to predict the course of the disease based solely on clinical parameters. In the present study, we built a robust prediction model using representative plasma biomarkers and clinical parameters for 90-day all-cause mortality. Risk prediction based on immune biomarkers and clinical variables may contribute to treatment selection for patients as well as provide insight into the role of immune system in C. difficile pathogenesis.


Asunto(s)
Infecciones por Clostridium/inmunología , Infecciones por Clostridium/mortalidad , Citocinas/sangre , Anciano , Biomarcadores/sangre , Clostridioides difficile/patogenicidad , Infecciones por Clostridium/diagnóstico , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/inmunología , Infección Hospitalaria/microbiología , Citocinas/inmunología , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Mortalidad , Medicina de Precisión , Modelos de Riesgos Proporcionales , Recurrencia , Estudios Retrospectivos , Factores de Riesgo
11.
PLoS One ; 15(3): e0230336, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32214325

RESUMEN

INTRODUCTION: Evidence implicates vitamin D deficiency in poorer outcomes and increased susceptibility to hospital-acquired infections (HAIs). This study examined the association between serum vitamin D levels and HAIs in a population of hepatobiliary surgery patients. METHODS: Participants in this prospective analytical observational study were patients who underwent hepatobiliary surgery in a tertiary hospital in Aragon, Spain, between February 2018 and March 2019. Vitamin D concentrations were measured at admission and all nosocomial infections during hospitalization and after discharge were recorded. RESULTS: The mean 25-hydroxyvitamin D concentration of the study population (n = 301) was 38.56 nmol/L, which corresponds to vitamin D deficiency. Higher vitamin D concentrations were associated with a decreased likelihood of developing a HAI in general (p = 0.014), and in particularly surgical site infection (p = 0.026). The risk of HAI decreased by 34% with each 26.2-nmol/L increase in serum vitamin D levels. CONCLUSIONS: Vitamin D levels may constitute a modifiable risk factor for postoperative nosocomial infections in hepatobiliary surgery patients.


Asunto(s)
Infección Hospitalaria/epidemiología , Procedimientos Quirúrgicos del Sistema Digestivo/efectos adversos , Complicaciones Posoperatorias/epidemiología , Deficiencia de Vitamina D/diagnóstico , Vitamina D/análogos & derivados , Anciano , Infección Hospitalaria/inmunología , Infección Hospitalaria/microbiología , Infección Hospitalaria/prevención & control , Femenino , Enfermedades Gastrointestinales/cirugía , Mortalidad Hospitalaria , Humanos , Masculino , Persona de Mediana Edad , Readmisión del Paciente/estadística & datos numéricos , Complicaciones Posoperatorias/inmunología , Complicaciones Posoperatorias/microbiología , Complicaciones Posoperatorias/prevención & control , Periodo Preoperatorio , Estudios Prospectivos , Factores de Riesgo , España/epidemiología , Infección de la Herida Quirúrgica , Centros de Atención Terciaria/estadística & datos numéricos , Vitamina D/sangre , Deficiencia de Vitamina D/complicaciones , Deficiencia de Vitamina D/epidemiología , Deficiencia de Vitamina D/inmunología
12.
Microbiol Immunol ; 64(2): 87-98, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31769530

RESUMEN

Burkholderia cepacia complex (Bcc) are opportunistic pathogens implicated with nosocomial infections, and high rates of morbidity and mortality, especially in individuals with cystic fibrosis (CF). B. cepacia are naturally resistant to different classes of antibiotics, and can subvert the host innate immune responses by producing quorum sensing (QS) controlled virulence factors and biofilms. It still remains a conundrum as to how exactly the bacterium survives the intracellular environment within the host cells of CF patients and immunocompromised individuals although the bacterium can invade human lung epithelial cells, neutrophils, and murine macrophages. The mechanisms associated with intracellular survival in the airway epithelial cells and the role of QS and virulence factors in B. cepacia infections in cystic fibrosis remain largely unclear. The current review focuses on understanding the role of QS-controlled virulence factors and biofilms, and provides additional impetus to understanding the potentials of QS-inhibitory strategies against B. cepacia.


Asunto(s)
Biopelículas , Infecciones por Burkholderia , Burkholderia cepacia/patogenicidad , Fibrosis Quística/microbiología , Percepción de Quorum/inmunología , Animales , Biopelículas/efectos de los fármacos , Biopelículas/crecimiento & desarrollo , Infecciones por Burkholderia/etiología , Infecciones por Burkholderia/inmunología , Burkholderia cepacia/crecimiento & desarrollo , Complejo Burkholderia cepacia/patogenicidad , Enfermedades Transmisibles Emergentes , Infección Hospitalaria/inmunología , Fibrosis Quística/complicaciones , Fibrosis Quística/inmunología , Síndrome de Liberación de Citoquinas , Farmacorresistencia Bacteriana Múltiple , Humanos , Evasión Inmune , Huésped Inmunocomprometido , Inflamación , Lipasa/metabolismo , Lipopolisacáridos/metabolismo , Pulmón/microbiología , Macrófagos/microbiología , Metaloendopeptidasas/metabolismo , Ratones , Neutrófilos/inmunología , Sideróforos/metabolismo , Factores de Virulencia/metabolismo
13.
Semin Respir Crit Care Med ; 40(4): 498-507, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31585476

RESUMEN

With the overall improvement in survival of cancer patients and the widespread use of novel immunotherapy drugs for malignant as well as nonmalignant diseases, the prevalence of immunosuppression is rising in the population. Immunocompromised patients are particularly exposed to pulmonary infections which remain a leading cause for acute hypoxic respiratory failure and intensive care unit admission. Although fungal or opportunistic infections are always a concern, bacterial pneumonia remains the most common cause of pulmonary infection, is associated with a significant mortality, and has some specificity in this population. Adequate and timely prevention, diagnosis, and management of bacterial pneumonias require knowledge about the complex interplay between host factors (type and severity of immunosuppression) and bacterial pathogenesis, to improve the outcome. We provide an overview of bacterial pneumonias in immunocompromised patients including their epidemiology, risk factors with respect to the pattern of immunosuppression, microbiological characteristics, diagnostic approach, management, and prevention.


Asunto(s)
Antibacterianos/uso terapéutico , Infección Hospitalaria/inmunología , Huésped Inmunocomprometido , Neumonía Bacteriana/inmunología , Antibacterianos/farmacología , Supervivientes de Cáncer , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/epidemiología , Humanos , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/epidemiología , Factores de Riesgo
14.
J Clin Immunol ; 39(8): 753-761, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31432442

RESUMEN

Severe combined immune deficiency (SCID) is caused by an array of genetic disorders resulting in a diminished adaptive immune system due to impaired T lymphocytes. In these patients, active infection at the time of hematopoietic transplantation has been shown to increase morbidity and mortality. To prevent transmission of infections in SCID patients, standardized infection control precautions should be implemented. An online survey regarding SCID-specific protocols was distributed through several immunodeficiency organizations. Seventy-three responses were obtained, with the majority (55%) of responses from the USA, 15% from Canada, and the remainder from 12 other countries. Only 50% of respondents had a SCID-specific infection control protocol at their center, and while a majority of these centers had training for physicians, a small minority had training for other healthcare workers such as nursing and housekeeping staff. Significant variability of infection control practices, such as in-patient precautions, required personal protective equipment (PPE), diet restrictions, visitor precautions and discharge criteria, was found between different treatment centers. There is a paucity of evidence-based data regarding the safest environment to prevent infection in SCID patients. Institutional protocols may have significant impact on infection risk, survival, family well-being, child development and cost of care. From these results, it is evident that further multi-center research is required to determine the safest and healthiest environment for these children, so that evidence-based infection control protocols for patients with SCID can be developed.


Asunto(s)
Infección Hospitalaria/prevención & control , Medicina Basada en la Evidencia/estadística & datos numéricos , Control de Infecciones/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Inmunodeficiencia Combinada Grave/inmunología , Lactancia Materna , Cuidadores/normas , Protocolos Clínicos , Infección Hospitalaria/inmunología , Medicina Basada en la Evidencia/instrumentación , Medicina Basada en la Evidencia/organización & administración , Medicina Basada en la Evidencia/normas , Trasplante de Células Madre Hematopoyéticas/normas , Humanos , Higiene/normas , Lactante , Recién Nacido , Control de Infecciones/instrumentación , Control de Infecciones/organización & administración , Control de Infecciones/normas , Educación del Paciente como Asunto , Equipo de Protección Personal/normas , Pautas de la Práctica en Medicina/organización & administración , Pautas de la Práctica en Medicina/normas , Inmunodeficiencia Combinada Grave/cirugía , Encuestas y Cuestionarios/estadística & datos numéricos
15.
Rev Med Chil ; 147(2): 256-260, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31095177

RESUMEN

Adenovirus (ADV) is a recognized cause of severe disease among immunocompromised patients. We report a previously healthy 39-year-old female, admitted with influenza pneumonia and evolving with lung hemorrhage and acute renal failure requiring mechanical ventilation and hemodialysis. She received high corticosteroid doses due to an initial suspicion of alveolar hemorrhage. Lymphopenia already present before steroid use (567/µL), was maintained during the whole hospital stay (mean 782/µL). From the second week of admission she presented a high-volume diarrhea (mean 2.5 L/day) associated to intermittent bloody stools. An ulcerative enterocolitis was confirmed by CT images and colonoscopy. ADV was detected in a colonic tissue sample by real time PCR but not by a commercial filmarray test. Cidofovir-probenecid and racecadotril therapy were indicated without changing the clinical course of diarrhea and the patient finally died.


Asunto(s)
Infecciones por Adenoviridae/complicaciones , Infección Hospitalaria/etiología , Enterocolitis/etiología , Hemorragia Gastrointestinal/etiología , Huésped Inmunocomprometido , Adenoviridae/aislamiento & purificación , Infecciones por Adenoviridae/microbiología , Adulto , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/inmunología , Diarrea/complicaciones , Enterocolitis/diagnóstico , Enterocolitis/inmunología , Resultado Fatal , Femenino , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/inmunología , Humanos
16.
Rev. méd. Chile ; 147(2): 256-260, Feb. 2019. graf
Artículo en Inglés | LILACS | ID: biblio-1004341

RESUMEN

ABSTRACT Adenovirus (ADV) is a recognized cause of severe disease among immunocompromised patients. We report a previously healthy 39-year-old female, admitted with influenza pneumonia and evolving with lung hemorrhage and acute renal failure requiring mechanical ventilation and hemodialysis. She received high corticosteroid doses due to an initial suspicion of alveolar hemorrhage. Lymphopenia already present before steroid use (567/μL), was maintained during the whole hospital stay (mean 782/μL). From the second week of admission she presented a high-volume diarrhea (mean 2.5 L/day) associated to intermittent bloody stools. An ulcerative enterocolitis was confirmed by CT images and colonoscopy. ADV was detected in a colonic tissue sample by real time PCR but not by a commercial filmarray test. Cidofovir-probenecid and racecadotril therapy were indicated without changing the clinical course of diarrhea and the patient finally died.


Adenovirus (ADV) es una causa reconocida de enfermedades graves en pacientes inmunocomprometidos. Informamos el caso de una mujer de 39 años, previamente sana, que ingresó por neumonía grave por influenza, evolucionando con hemorragia pulmonar y falla renal aguda, requiriendo ventilación mecánica y hemodiálisis. Recibió altas dosis de corticoides por la sospecha inicial de una hemorragia alveolar. Tuvo linfopenia durante toda su estadía (promedio 782/μL), la que ya estaba presente antes del uso de los corticoides (567/μL). Desde la segunda semana de hospitalización, presentó una diarrea de alto volumen (promedio 2,5 L/día) asociada a la presencia de sangre en deposiciones en forma intermitente. Se confirmó una enterocolitis ulcerativa por tomografía computada y colonoscopía. Se detectó ADV en muestras de biopsia colónica por PCR en tiempo real pero no por un test de PCR múltiples automatizado comercial. Fue tratada con cidofovir-probenecid y racecadrotrilo sin impacto clínico y la paciente finalmente falleció.


Asunto(s)
Humanos , Femenino , Adulto , Infección Hospitalaria/etiología , Huésped Inmunocomprometido , Infecciones por Adenoviridae/complicaciones , Enterocolitis/etiología , Hemorragia Gastrointestinal/etiología , Adenoviridae/aislamiento & purificación , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/inmunología , Resultado Fatal , Infecciones por Adenoviridae/microbiología , Diarrea/complicaciones , Enterocolitis/diagnóstico , Enterocolitis/inmunología , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/inmunología
17.
Crit Rev Immunol ; 39(3): 151-163, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-32421960

RESUMEN

Staphylococcus epidermidis is one of the major causes of nosocomial infections in humans. This organism can exist as a commensal on the skin. However, it can also lead to severe infections. The immune system has evolved mechanisms to deal with microorganisms and has strategies to combat bacteria. The initial defense against S. epidermidis infections includes the activation of complement complex, recruitment and then killing of the microorganism by effectors. The success of pathogenic S. epidermidis strains has been attributed to their capacity to evade innate immune cells. Extracellular matrix binding protein, polysaccharide intercellular adhesin, and accumulation-associated protein have been found to suppress killing of S. epidermidis by effector cells. PSM constitutes the only kind of exported toxins in S. epidermidis strains and has strong cytolytic features against leukocyte cells. The human innate immune system can be stimulated against S. epidermidis via toll-like receptors that enhance antibacterial reactions, trigger inflammation, and result in the stimulation of immune system effectors, e.g., type-1 interferon (IFN-alpha and IFN-beta), proinflammatory cytokines, and nitric oxide. Proinflammatory cytokines, e.g., interleukin-1, interleukin-6, and tumor necrosis factor are formed from resident human cells and result in migration of the lymphocyte and fever. In this review we will examine the immune system's response against S. epidermidis.


Asunto(s)
Infección Hospitalaria/inmunología , Matriz Extracelular/metabolismo , Inflamación/inmunología , Infecciones Estafilocócicas/inmunología , Staphylococcus epidermidis/fisiología , Biopelículas , Citocinas/metabolismo , Humanos , Evasión Inmune , Sistema Inmunológico , Inmunidad Innata
18.
J Heart Lung Transplant ; 37(8): 1001-1012, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29754764

RESUMEN

BACKGROUND: Infection is still a leading cause of death during the first year after lung transplantation. We performed a multicenter study among teaching hospitals to assess monitoring of early humoral immunity as a means of identifying lung recipients at risk of serious infections. METHODS: We prospectively analyzed 82 adult lung recipients at 5 centers in Spain. Data were collected before transplantation and at 7 and 30 days after transplantation. Biomarkers included IgG, IgM, IgA, complement factors C3 and C4, titers of antibodies to pneumococcal polysaccharide antigens (IgG, IgA, IgM) and antibodies to cytomegalovirus (IgG), and serum B-cell activating factor (BAFF) levels. The clinical follow-up period lasted 6 months. Clinical outcomes were bacterial infections requiring intravenous anti-microbial agents, cytomegalovirus (CMV) disease, and fungal infections requiring therapy. RESULTS: We found that 33 patients (40.2%) developed at least 1 serious bacterial infection, 8 patients (9.8%) had CMV disease, and 10 patients (12.2%) had fungal infections. Lower IgM antibody levels against pneumococcal polysaccharide antigens at Day 7 (defined as <5 mg/dl) were a risk factor for serious bacterial infection (adjusted odds ratio [OR] 3.96; 95% confidence interval [CI] 1.39 to 11.26; p = 0.0099). At Day 7 after transplantation, IgG hypogammaglobulinemia (defined as IgG <600 mg/dl) was associated with a higher risk of CMV disease (after adjustment for CMV mismatch: OR 8.15; 95% CI 1.27 to 52.55; p = 0.028) and fungal infection (adjusted OR 8.03, 95% CI 1.51 to 42.72; p = 0.015). Higher BAFF levels before transplantation were associated with a higher rate of development of serious bacterial infection and acute cellular rejection. CONCLUSION: Early monitoring of specific humoral immunity parameters proved useful for the identification of lung recipients who are at risk of serious infections.


Asunto(s)
Infección Hospitalaria/inmunología , Inmunidad Humoral/inmunología , Trasplante de Pulmón , Monitoreo Fisiológico , Infecciones Oportunistas/inmunología , Adulto , Agammaglobulinemia/diagnóstico , Agammaglobulinemia/inmunología , Anciano , Formación de Anticuerpos/inmunología , Factor Activador de Células B/sangre , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/inmunología , Biomarcadores/sangre , Infección Hospitalaria/diagnóstico , Infecciones por Citomegalovirus/diagnóstico , Infecciones por Citomegalovirus/inmunología , Diagnóstico Precoz , Femenino , Humanos , Masculino , Persona de Mediana Edad , Micosis/diagnóstico , Micosis/inmunología , Infecciones Oportunistas/diagnóstico , Estudios Prospectivos , Factores de Riesgo
19.
Pediatr Infect Dis J ; 37(10): 1034-1040, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29570588

RESUMEN

BACKGROUND: To longitudinally study blood monocyte subset distribution and human leukocyte antigen-DR (HLA-DR) expression on monocyte subsets in children with sepsis, post-surgery and trauma in relation to nosocomial infections and mortality. METHODS: In 37 healthy children and 37 critically ill children (12 sepsis, 11 post-surgery, 10 trauma and 4 admitted for other reasons)-participating in a randomized controlled trial on early versus late initiation of parenteral nutrition-monocyte subset distribution and HLA-DR expression on monocyte subsets were measured by flow cytometry upon admission and on days 2, 3 and 4 of pediatric intensive care unit (PICU) stay. RESULTS: Upon PICU admission, critically ill children had a higher proportion of classical monocytes (CD14++CD16-) than healthy children [PICU 95% (interquartile range [IQR] 88%-98%); controls, 87% (IQR 85%-90%), P < 0.001]. HLA-DR expression was significantly decreased within all monocyte subsets and at all time points, being most manifest on classical monocytes and in patients with sepsis. Percentage of HLA-DR expressing classical monocytes [upon PICU admission 67% (IQR 44%-88%); controls 95% (IQR 92%-98%), P < 0.001], as well as the HLA-DR mean fluorescence intensity [upon PICU admission 3219 (IQR 2650-4211); controls 6545 (IQR 5558-7647), P < 0.001], decreased during PICU stay. Patients who developed nosocomial infections (n = 13) or who died (n = 6) had lower HLA-DR expression on classical monocytes at day 2 (P = 0.002) and day 3 (P = 0.04), respectively. CONCLUSIONS: Monocytic HLA-DR expression decreased during PICU stay and was lower compared with controls on all examined time points, especially on classical monocytes and in children admitted for sepsis. Low HLA-DR expression on classical monocytes was associated with nosocomial infections and death.


Asunto(s)
Expresión Génica , Antígenos HLA-DR/genética , Monocitos/inmunología , Adolescente , Niño , Preescolar , Enfermedad Crítica , Infección Hospitalaria/inmunología , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Lactante , Recién Nacido , Unidades de Cuidado Intensivo Pediátrico/estadística & datos numéricos , Estudios Longitudinales , Masculino , Monocitos/clasificación , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , Sepsis/inmunología , Heridas y Lesiones/inmunología
20.
Ann Hematol ; 97(2): 343-350, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29138886

RESUMEN

Stenotrophomonas maltophilia (SM) has emerged as an important nosocomial pathogen with high morbidity and mortality. Because of its unique antimicrobial susceptibility pattern, appropriate antimicrobial therapy for SM bacteremia is still challenging, especially in immunocompromised patients. The present study was performed to assess clinical predictors of SM bacteremia in adult patients with hematologic malignancy. From 2006 through 2016, a case-control study was performed at a tertiary-care hospital. Case patients were defined as SM bacteremia in patients with hematologic malignancy. Date- and location-matched controls were selected from among patients with gram-negative bacteremia (GNB) other than SM. A total of 118 cases of SM bacteremia were identified and compared to 118 controls. While pneumonia was the most common source of SM bacteremia, centralline-associated infection was most common in the controls. The overall 30-day mortality rate of cases with SM bacteremia was significantly higher than that of the controls (61.0 and 32.2%, respectively; P < 0.001). A multivariable analysis showed that polymicrobial infection, previous SM isolation, the number of antibiotics previously used ≥ 3, and breakthrough bacteremia during carbapenem therapy were significantly associated with SM bacteremia (all P < 0.01). Previous use of trimethoprim/sulfamethoxazole (TMP/SMX) was negatively association with SM bacteremia (P = 0.002). Our data suggest that SM is becoming a significant pathogen in patients with hematologic malignancy. Several clinical predictors of SM bacteremia can be used for appropriate antimicrobial therapy in hematologic patients with suspected GNB.


Asunto(s)
Infección Hospitalaria/diagnóstico , Infecciones por Bacterias Gramnegativas/diagnóstico , Neoplasias Hematológicas/diagnóstico , Huésped Inmunocomprometido , Neumonía/diagnóstico , Stenotrophomonas maltophilia/inmunología , Adulto , Anciano , Antibacterianos/uso terapéutico , Carbapenémicos/uso terapéutico , Estudios de Casos y Controles , Infección Hospitalaria/inmunología , Infección Hospitalaria/microbiología , Infección Hospitalaria/mortalidad , Femenino , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Gramnegativas/inmunología , Infecciones por Bacterias Gramnegativas/mortalidad , Neoplasias Hematológicas/inmunología , Neoplasias Hematológicas/microbiología , Neoplasias Hematológicas/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Neumonía/tratamiento farmacológico , Neumonía/inmunología , Neumonía/mortalidad , Pronóstico , Análisis de Supervivencia , Centros de Atención Terciaria , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA